パラビリス・メディシンズ
PBLS
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -2.32 | $148,000 | -$4M |
| 2026 Q1 | -34.58 | $0 | -$50M |
| 2025 Q2 | -0.36 | $0 | -$31M |
| 2025 Q1 | -23.84 | $0 | -$34M |